Article Text

PDF
▼Agomelatine for major depressive episodes

Abstract

▼Agomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug acts simultaneously as a melatonin receptor agonist and a serotonin receptor antagonist and claims that it is a “major therapeutic advance in management of depression through the restoration of circadian rhythms”.1 Here we consider whether agomelatine offers significant advantage for patients with major depressive episodes.

Statistics from Altmetric.com

  • Relevant BNF section: BNF 4.3.4

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.